OncoSil Medical Ltd
OSL
Company Profile
Business description
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil device, a localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company operates in one segment being the device development for new medical treatments. Geographically, it derives maximum revenue from Europe and the rest from Australia, the Middle East, and the United Kingdom.
Contact
7 Eden Park Drive
Level 5, Macquarie Park
SydneyNSW2113
AUST: +61 289359629
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
Employees
2
Stocks News & Analysis
stocks
Nvidia: Hugging Face acquisition both a wise offensive and defensive move
We think this improves Nvidia’s position within the open-source community.
stocks
Anthropic’s IPO will be huge—and risky. Here are the challenges investors should watch
Part two of a Q&A with PitchBook senior analyst Harrison Rolfes about Anthropic, the AI giant’s challenges, and how much it’s worth.
stocks
Chart of the Week: China demand for copper falls amidst record rally
Elevated copper prices raise valuation questions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,197.80 | 52.80 | -0.57% |
| CAC 40 | 8,286.40 | 5.77 | 0.07% |
| DAX 40 | 26,003.32 | 163.99 | 0.63% |
| Dow JONES (US) | 53,686.11 | 624.16 | 1.18% |
| FTSE 100 | 10,831.52 | 75.07 | 0.70% |
| HKSE | 25,734.82 | 521.51 | 2.07% |
| NASDAQ | 26,584.06 | 366.23 | 1.40% |
| Nikkei 225 | 65,106.60 | 892.12 | 1.39% |
| NZX 50 Index | 13,974.18 | 128.00 | 0.92% |
| S&P 500 | 7,747.71 | 81.11 | 1.06% |
| S&P/ASX 200 | 9,008.40 | 61.80 | -0.68% |
| SSE Composite Index | 3,967.05 | 24.96 | 0.63% |